Prof Gail Risbridger
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
203 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer
DOI: 10.1186/s13046-026-03659-w2026
Journal article
Abstract SY24-02: Di-codon organization links tRNA modifications to cancer cell proteome composition
DOI: 10.1158/1538-7445.am2026-sy24-022026
Journal article
Abstract 2697: Single-cell transcriptomic characterisation reveals pathway determinants of bipolar androgen therapy response in prostate cancer.
DOI: 10.1158/1538-7445.am2026-26972026
Journal article
A0396 Tumour cell evolution within patient-derived models of localised hereditary prostate cancer
DOI: 10.1016/s0302-2838(26)00451-32026
Book Chapter
Diseases of the Prostate Gland
DOI: 10.1016/b978-0-443-21477-6.00460-02025
Journal article
MON-312 Lewis Y Antigen as a Novel Target for CAR (Chimeric Antigen Receptor) T-cell Therapy in Patients with Neuroendocrine Prostate Cancer
DOI: 10.1210/jendso/bvaf149.24122022
Research grants (ARC, NHMRC, MRFF)
Developing Novel Car T Cell Therapy Approaches to Treat Prostate Cancer
RECENT SCHOLARLY WORKS
2025
Journal article
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
DOI: 10.1016/j.euf.2025.03.0172025
Journal article
Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide
DOI: 10.1158/1538-7445.am2025-71822024
Journal article
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer
DOI: 10.1038/s41467-024-49234-92024
Journal article
CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer
DOI: 10.1038/s41416-024-02810-8